-

12:58:11 PM

LPCN Stock News

LPCN - Lipocine Inc

05/12/22 8:00 AM

Nasdaq : LPCN

Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results

RHEA-AI

neutral

05/09/22 8:00 AM

Nasdaq : LPCN

earnings

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, today announced financial results for the quarter ended March 31, 2022 and provided a corporate

RHEA-AI

neutral

04/11/22 8:00 AM

Nasdaq : LPCN

LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, announced today the appointment of Jill M.

RHEA-AI

very positive

03/29/22 7:05 AM

Nasdaq : LPCN

fda approval

LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, announced today that Antares Pharma, Inc. issued a

RHEA-AI

very positive

03/09/22 8:00 AM

Nasdaq : LPCN

earnings

Lipocine Announces Financial Results for the Year Ended December 31, 2021

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate

RHEA-AI

neutral

03/01/22 8:00 AM

Nasdaq : LPCN

Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today provided an update from the Type C guidance meeting with the U.S. Food and Drug Administration ("FDA") regarding the

RHEA-AI

very positive

02/03/22 8:00 AM

Nasdaq : LPCN

LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO®

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products for metabolic and endocrine disorders, today announced that Antares Pharma, Inc. issued a press release announcing that the U.S. Food and

RHEA-AI

very positive

01/27/22 8:00 AM

Nasdaq : LPCN

clinical trial

Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO®

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the peer-reviewed publication of positive Phase 3 clinical data from the Dosing Validation ("DV") study which

RHEA-AI

neutral

01/05/22 8:00 AM

Nasdaq : LPCN

conferencesclinical trial

Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that one abstract has been selected for podium presentation and three abstracts have been selected for poster

RHEA-AI

neutral

12/22/21 8:00 AM

Nasdaq : LPCN

clinical trial

LIPOCINE ANNOUNCES PATIENT DOSED IN ITS PHASE 2 STUDY WITH LPCN 1148 FOR MANAGEMENT OF LIVER CIRRHOSIS

Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the first patient has been dosed in its Phase 2 proof-of-concept clinical study (NCT04874350) for the management

RHEA-AI

neutral

1 2 3 4 5 6 Next

LPCN Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.lipocine.com
CeoMahesh Patel
Security nameLipocine Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees11
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address675 S Arapeen Dr Ste 202
StateUtah
CitySalt Lake City
Zip84108-1295
CountryUS
Phone18019947383

About Lipocine Inc

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the U.S. Food and Drug Administration (the 'FDA') for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH. LPCN 1144 is currently being studied in a Phase 2 clinical study. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a Phase 2 clinical evaluation when administered once daily or twice daily, TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA.